Filing Details

Accession Number:
0001209191-22-001202
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-04 21:00:09
Reporting Period:
2021-12-30
Accepted Time:
2022-01-04 21:00:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1655759 Arvinas Inc. ARVN Pharmaceutical Preparations (2834) 472566120
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1783868 Ronald Peck C/O Arvinas, Inc.
5 Science Park, 395 Winchester Avenue
New Haven CT 06511
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-30 14,375 $47.38 19,777 No 4 M Direct
Common Stock Acquisiton 2021-12-30 5,625 $26.58 25,402 No 4 M Direct
Common Stock Disposition 2021-12-30 11,371 $80.35 14,031 No 4 S Direct
Common Stock Disposition 2021-12-30 8,629 $80.96 5,402 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-12-30 14,375 $0.00 14,375 $47.38
Common Stock Stock Option (right to buy) Disposition 2021-12-30 5,625 $0.00 5,625 $26.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
40,625 2030-02-26 No 4 M Direct
46,559 2029-07-28 No 4 M Direct
Footnotes
  1. The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.76 to $80.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.
  5. This option award was granted on February 27, 2020. 1/4 of the shares underlying the award vested on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.
  6. This option award was granted on July 29, 2019. 1/4 of the shares underlying the award vested on July 29, 2020, with the remainder of the shares vesting in equal monthly installments following July 29, 2020 through July 29, 2023.